

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7572470

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CLEO LIFE SCIENCES	02/01/2017
RECEIVING PARTY DATA	
Name:	KEZAR LIFE SCIENCES
Street Address:	4000 SHORELINE COURT
Internal Address:	STE. 300
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17953935
CORRESPONDENCE DATA	
Fax Number:	(312)474-0448
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3124746300
Email:	docket@marshallip.com
Correspondent Name:	MARSHALL, GERSTEIN & BORUN LLP
Address Line 1:	233 S WACKER DRIVE
Address Line 2:	SUITE 6300
Address Line 4:	CHICAGO, ILLINOIS 60606
ATTORNEY DOCKET NUMBER:	32623/40053C US CLEO TO K
NAME OF SUBMITTER:	SHELLEY DANEK
SIGNATURE:	/Shelley Danek/
DATE SIGNED:	10/04/2022
Total Attachments: 1	
source=Executed Assignment Cleo to Kezar#page1.tif	

CONFIRMATORY ASSIGNMENT

This assignment agreement ("Assignment") is effective as of June 29, 2016 ("Effective Date") and entered into by and between Cleo Life Sciences located at 1220 Balboa Avenue, Burlingame, California 94010 ("Assignor") and Kezar Life Sciences located at 300 Utah Street, Suite South San Francisco, California 94080 ("Assignee").

This assignment agreement is in compliance with and incorporates the terms outlined in the Consulting Agreement between Assignor and Assignee, dated June 15, 2015.

For good and valuable consideration, the receipt and sufficiency of which are agreed, Assignor hereby irrevocably sells, assigns and transfers to Assignee and its successors, assigns and legal representatives, Assignor's entire right, title and interest, both legal and equitable, in U.S. Patent Application Serial No. 62/356,287, filed June 29, 2016, and to the inventions described therein and improvements thereof, all related patent applications throughout the world including those claiming priority thereto anywhere in the world, the right of priority, including without limitation to claim priority benefit of or to said patent applications, all continuations, divisionals and continuations-in-part of any of the foregoing, patents issuing from any of the foregoing, and reissues, reexaminations, extensions and foreign equivalents thereof and supplementary protection certificates allowed on any of the foregoing (collectively the "Patent Rights") for Assignee's own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made; together with all income, royalties, damages or payments due or payable as of the Effective Date or thereafter, including, without limitation, all claims for damages by reason of past, present or future infringement or other unauthorized use of the Patent Rights, with the right to sue for, and collect the same for its own use and enjoyment, and for the use and enjoyment of its successors, assigns, or other legal representatives.

Upon the request of Assignee, the undersigned agrees to execute any and all documents and take actions reasonably requested to effectuate this assignment and Assignee's rights in the Patent Rights, including any oath or affidavit relating thereto, to cooperate to the best of the ability of the undersigned with Assignee in preparing and executing statements and giving and producing evidence in support of the Patent Rights, and to perform any and all acts reasonably requested by Assignee to obtain, enforce and defend the Patent Rights and vest all rights therein to Assignee as fully and entirely as the same would have been held and enjoyed by the undersigned if this Assignment had not been executed.

The parties execute and deliver this Assignment by their respective signatories below.

Cleo Life Sciences

Kezar Life Sciences

x 

x 

Name: SEAN DALZIEL

Name: Christopher Kirk

Title: MANAGING DIRECTOR

Title: President & CEO

Date: 01 FEB 2017

Date: 2 FEB 2017

PATENT